FATTA, ERIKA
 Distribuzione geografica
Continente #
EU - Europa 2348
NA - Nord America 766
AS - Asia 495
SA - Sud America 30
AF - Africa 3
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3645
Nazione #
GB - Regno Unito 1153
US - Stati Uniti d'America 733
DE - Germania 348
CN - Cina 268
IT - Italia 264
SE - Svezia 175
RU - Federazione Russa 120
UA - Ucraina 112
TR - Turchia 105
KR - Corea 65
EU - Europa 58
IN - India 48
PL - Polonia 45
FR - Francia 43
NL - Olanda 34
CA - Canada 33
FI - Finlandia 32
CO - Colombia 30
DK - Danimarca 7
GR - Grecia 7
RO - Romania 5
AU - Australia 2
IR - Iran 2
MA - Marocco 2
PK - Pakistan 2
SG - Singapore 2
AT - Austria 1
BE - Belgio 1
ES - Italia 1
GH - Ghana 1
HK - Hong Kong 1
JP - Giappone 1
UZ - Uzbekistan 1
Totale 3702
Città #
Southend 1091
Milan 102
Seattle 91
Beijing 89
Jacksonville 89
Princeton 73
Mountain View 58
Dearborn 56
Redmond 46
Serra 46
Warsaw 45
Ann Arbor 44
Nanjing 44
Wilmington 41
Somerville 40
Toronto 32
Andover 31
Sakarya 31
Bogotá 30
Munich 26
Saint Petersburg 22
Chandler 21
Des Moines 19
Woodbridge 19
Jinan 16
Fuzhou 14
Kiez 14
Nürnberg 14
Bitonto 13
Shenyang 9
Tianjin 9
Grafing 8
Hebei 8
Rome 8
Ashburn 7
Athens 7
Fairfield 7
Nanchang 7
Changsha 6
Haikou 6
Hamburg 6
Hangzhou 6
Jiaxing 6
Kunming 6
Noginsk 6
San Diego 6
Zhengzhou 6
Verona 5
Guangzhou 4
Lissone 4
Odernheim 4
Redwood City 4
Shanghai 4
Boardman 3
Chengdu 3
Houston 3
Mumbai 3
Ningbo 3
Pskov 3
Roxbury 3
Solofra 3
Taizhou 3
Bergamo 2
Changchun 2
Cupertino 2
Fremont 2
Lanzhou 2
Mainz 2
Mohammedia 2
Motta Visconti 2
Palaiseau 2
Portici 2
Scranton 2
Singapore 2
Sunnyvale 2
Zoagli 2
Accra 1
Alpharetta 1
Atlanta 1
Auburn Hills 1
Berlin 1
Bismarck 1
Boston 1
Brussels 1
Buscate 1
Cambridge 1
Campagna 1
Casalecchio di Reno 1
Chandigarh 1
Düsseldorf 1
Frankfurt 1
Hanyang 1
Hefei 1
Kwai Chung 1
Lizzanello 1
London 1
Los Angeles 1
Lucca 1
Madrid 1
Maidstone 1
Totale 2485
Nome #
Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice : the Italian multicenter experience 312
Risk of NASH and severe fibrosis in patients with NAFLD and low visceral adiposity 196
Variables significantly associated with non alcoholic steatohepatitis (NASH) and fibrosis in patients with non alcoholic fatty liver disease (NAFLD) 163
Cell-free DNA in HCV-related cirrhosis and small hepatocellular carcinoma 136
Cell-free DNA in HCV-related cirrhosis and small hepatocellular carcinoma 134
Increased ferritin predicts vascular damage in patients with nonalcoholic fatty liver disease 130
Progression of carotic atherosclerotic damage is related to alt values in patients with non alcoholic fatty liver disease 129
Increased ferritin predicts vascular damage in patients with nonalcoholic fatty liver disease 125
Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients 124
Effectiveness of Entecavir for the treatment of NUC-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 122
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels : a role for insulin resistance and diabetes 120
Entecavir is an effective treatment for NUC-naive chronic hepatitis B patients in clinical practice : 48-week data from a large multicenter cohort study 117
Normal ALT NAFLD should not preclude liver biopsy 116
Effectiveness of entecavir for the treatment of nuc-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 115
Entecavir for nuc-naïve chronic hepatitis B patients in clinical practice : long-term effectiveness from a large multicenter cohort study in 376 patients 115
Baseline alt and ferritin predict histological findings in NAFLD 112
Risk of early atherosclerosis by carotid artery intima- media thickness in patients with non alcoholic fatty liver disease and low visceral adiposity 111
Risk of NASH and severe fibrosis in patients with NAFLD and low visceral adiposity 110
The risk of severe liver disease in NAFLD with normal amino-transferase levels : a role for insulin and diabetes 110
Iron depletion by phlebotomy improves liver transaminases in patients with nonalcoholic fatty liver disease : a propensity score adjusted analysis 109
Progression of carotic atherosclerotic damage is related to ALT values 108
Normal ALT should not preclude liver biopsy in patients with NAFLD 107
Effectiveness of entecavir for the treatment of NUC-naïve chronic hepatitis B patients : A large multicenter cohort study in clinical practice 105
Ferro, steatosi e... 104
Baseline alt and ferritin predict histological findings in NAFLD 103
Evaluation of patients with NAFLD with or without increased ALT 103
Effectiveness of Entecavir for NUC-naïve, HBeAg-negative chronic hepatitis B patients in clinical practice : a 2-year multicenter cohort study in 311 patients 102
Contrast-enhanced ultrasonography (CEUS) and spiral computed tomography (CT) in the assessement of efficacy of percutaneous ablation treatments of hepatocellular carcinoma in cirrhosis 101
Risk of early atherosclerosis by carotid artery intima-media thickness in patients with non-alcoholic fatty liver disease and low visceral adiposity 100
Entecavir for nuc-naïve chronic hepatitis b patients in clinical practice : long-term effectiveness from a large multicenter cohort study in 376 patients 98
A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia 95
Effectiveness of entecavir for NUC-naïve, HBeAg-negative chronic hepatitis B patients in clinical practice : a 2-year multicenter cohort study in 311 patients 80
Interaction between lifestyle changes and PNPLA3 genotype in NAFLD patients during the COVID-19 lockdown 13
Totale 3925
Categoria #
all - tutte 4368
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4368


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018469 0633184 5544 3315 3196638
2018/2019492 114211566 1247 6116 58402517
2019/2020557 47192070 1694 4040 9382315
2020/2021561 842642 3628 4520 653816350
2021/2022365 178734 817 4039 40553367
2022/202361 61000 00 00 0000
Totale 3925